What's new

Human medicines European public assessment report (EPAR): Xenpozyme, olipudase alfa, Date of authorisation: 24/06/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Xenpozyme, olipudase alfa, Date of authorisation: 24/06/2022, Revision: 7, Status: Authorised

May 27, 2025 - 16:15
 0
Human medicines European public assessment report (EPAR): Xenpozyme, olipudase alfa, Date of authorisation: 24/06/2022, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Xenpozyme, olipudase alfa, Date of authorisation: 24/06/2022, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

GlycoEra’s global jobs underscore U.S. brain drain

Next Article

Human medicines European public assessment report (EPAR): Galafold, migalastat, ...

Related Posts

ICH M11 guideline, clinical study protocol template and technical specifications - Scientific guideline

ICH M11 guideline, clinical study protocol template and...

May 23, 2025  0

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR...

May 14, 2025  0

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

May 19, 2025  0